{"paper_id":"e3e7d460-fc17-46e8-aee1-2ce2bd403c8f","body_text":"Clin. Exp. Obstet. Gynecol. 2026; 53(10): 50028\nhttps://doi.org/10.31083/CEOG50028\nCopyright: © 2026 The Author(s). Published by IMR Press.\nThis is an open access article under the CC BY 4.0 license .\nPublisher’s Note: IMR Press stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.\nOriginal Research\nImpact of Pretreatment With a Gonadotropin-Releasing Hormone\nAgonist and Letrozole on In Vitro Fertilization Outcomes in Normal\nResponders With Ovarian Endometrioma\nQingqing Sun1,*\n , Yijuan Cao1, Juan Gu 1, Y aru Y ang1\n1Reproductive Medical Center, Xuzhou Central Hospital, Southeast University, 221009 Xuzhou, Jiangsu, China\n*Correspondence: southeastsun@163.com (Qingqing Sun)\nAcademic Editor: David H. Barad\nSubmitted: 15 January 2026 Revised: 21 April 2026 Accepted: 30 April 2026 Published: 16 October 2026\nAbstract\nBackground: The optimal pretreatment strategy for patients with ovarian endometrioma (OEM) undergoing in vitro fertilization (IVF)\nremains controversial, particularly among those with a normal ovarian response. Letrozole (LE) has been proposed to modulate the\novarian hormonal environment and improve ovarian stimulation outcomes. However, its clinical value in this patient population has not\nbeen fully established. We assessed the clinical value of pretreatment with LE in combination with a gonadotropin-releasing hormone\nagonist (GnRHa) in patients with OEM and normal ovarian response undergoing IVF. Methods: In this retrospective study, 71 patients\nwith OEM and normal ovarian response who underwent IVF-embryo transfer (IVF-ET) were initially enrolled and assigned to the GnRHa\n+ LE group (n = 36) or the GnRHa group (n = 35). After one patient was excluded from each group, 35 patients in the GnRHa + LE\ngroup and 34 patients in the GnRHa group were included in the final transfer-cycle analysis. During controlled ovarian stimulation,\npatients received pretreatment with GnRHa (3.75 mg) either alone or in combination with LE (2.5 mg) and were accordingly allocated\nto the GnRHa group or the GnRHa + LE group. Between-group differences were evaluated regarding baseline characteristics, ovarian\nstimulation profiles, and reproductive outcomes. Results: The total gonadotropin dose was significantly lower in the GnRHa + LE group\nand was accompanied by reduced serum estradiol levels on the trigger day ( p < 0.01). This group also demonstrated increased numbers\nof retrieved and metaphase II oocytes (all p < 0.01), as well as improved fertilization rates ( p = 0.02) and day-3 high-quality embryo rates\n(p < 0.05). Stimulation duration, cleavage rate, progesterone levels, embryo transfer number, endometrial thickness, and fresh embryo\ntransfer cancellation rates did not differ significantly between groups (all p > 0.05). The clinical pregnancy rate was significantly higher\nin the GnRHa + LE group ( p = 0.04). The implantation rate was significantly higher in the GnRHa + LE group than in the GnRHa\ngroup (p = 0.04), whereas the early miscarriage rate was comparable between the two groups ( p = 0.82). Reduction in maximal ovarian-\nendometriotic-cyst diameter was significantly greater in the GnRHa + LE group ( p = 0.04). Conclusions: Combined pretreatment with\nLE and GnRHa may enhance ovarian response efficiency and improve IVF-ET outcomes among women with OEM who exhibit a normal\novarian response.\nKeywords: gonadotropin-releasing hormone agonist; infertility; in vitro fertilization; letrozole; normal ovarian response; ovarian en-\ndometrioma\n1. Introduction\nEndometriosis is a chronic estrogen-dependent gyne-\ncological disorder characterized by the ectopic presence of\nfunctional endometrial-like tissue outside the uterine cav-\nity, and is commonly associated with dysmenorrhea, pelvic\npain, infertility, and impaired organ function. It affects\napproximately 10%–20% of women of reproductive age,\nwith up to 50% experiencing infertility [ 1]. Moreover, be-\nyond its clinical manifestations, endometriosis is associated\nwith a compromised reproductive microenvironment, in-\ncluding chronic inflammation, immune dysregulation, and\nimpaired endometrial receptivity, which may adversely af-\nfect assisted reproductive technology outcomes.\nOvarian endometrioma (OEM) is the most common\nsubtype among infertile women, with approximately 17%–\n44% of patients undergoing assisted reproductive treat-\nment, including in vitro fertilization and embryo transfer\n(IVF-ET), being affected. Ovarian endometriomas may ad-\nversely affect fertility and reproductive outcomes in women\nwith endometriosis [2]. In addition, OEM has been reported\nto adversely affect IVF outcomes by decreasing oocyte\nquality, reducing fertilization rates, impairing embryo de-\nvelopment, and increasing the risk of implantation failure\nand early pregnancy loss.\nGonadotropin-releasing hormone agonists (GnRHa)\nremain a key medical therapy for endometriosis and are\nwidely integrated into IVF-ET protocols. Sallam et al. [ 3]\nreported that 3–6 months of GnRHa pretreatment increased\nclinical pregnancy rates in women with endometriosis by\nnearly fourfold. Long-acting GnRHa before embryo trans-\nfer has also been shown to lower early miscarriage rates [4].\nHowever, evidence regarding GnRHa-induced reduction of\novarian endometriotic cysts is inconsistent, likely due to in-\nsufficient suppression of extragonadal estrogen production\n[5].\n\nMechanistically, GnRHa treatment initially induces a\ntransient flare-up effect followed by downregulation of pi-\ntuitary gonadotropin secretion, leading to profound hypoe-\nstrogenism and suppression of endometriotic lesion activ-\nity. This hypoestrogenic state contributes to reduced lesion\nproliferation, decreased inflammatory cytokine production,\nand improved pelvic environment [ 1,5].\nLetrozole (LE), a selective aromatase inhibitor, sup-\npresses both intra- and extra-ovarian estrogen biosynthe-\nsis, thereby inhibiting estrogen-dependent lesion growth.\nIn one study, three months of high-dose LE (5 mg/day)\ncombined with a progestin reduced mean cyst diameter by\nabout 50% and cyst volume by 75% [ 6]. At the molec-\nular level, LE inhibits the aromatase enzyme responsible\nfor the peripheral conversion of androgens to estrogens,\nthereby reducing both systemic and local estrogen concen-\ntrations. This dual suppression is particularly relevant in\nendometriosis, where ectopic lesions exhibit aberrant aro-\nmatase expression and local estrogen production [ 6].\nGiven the complementary mechanisms of GnRHa and\nLE, we hypothesized that combined pretreatment would\nenhance IVF outcomes in OEM patients. Specifically,\nwhereas GnRHa suppresses ovarian estrogen production\nvia pituitary downregulation, LE further inhibits peripheral\nand local estrogen synthesis, potentially resulting in more\ncomplete estrogen deprivation and improved control of en-\ndometriotic activity. This study therefore evaluated the\nclinical value of GnRHa plus LE pretreatment in normal-\nresponder women with OEM who were undergoing IVF-\nET.\n2. Materials and Methods\n2.1 Study Sample\nA total of 125 patients with OEMs and normal ovarian\nresponse who underwent IVF-ET at the Reproductive Cen-\nter of Xuzhou Central Hospital between March 2023 and\nMarch 2025 were initially assessed for eligibility. OEM\nwas not considered the sole cause of infertility in all cases;\ninstead, all patients had a confirmed diagnosis of OEM, al-\nthough additional infertility factors (such as tubal or male\nfactors) could coexist. Of these, 54 patients were excluded\nfor the following reasons: age <23 or >35 years (n = 21),\nfailure to meet the predefined criteria for normal ovarian re-\nsponse (n = 8), prior surgery for endometriosis (n = 9), uter-\nine abnormalities, endometrial disorders, or hydrosalpinx\npotentially affecting implantation (n = 11), and total motile\nsperm count <5 × 10 6 in the male partner (n = 5).\nUltimately, 71 patients were enrolled and assigned to\neither the GnRHa + LE group (n = 36) or the GnRHa group\n(n = 35), according to whether LE pretreatment was used.\nOne patient in each group was subsequently excluded (due\nto elevated progesterone level on trigger day in the GnRHa\n+ LE group and personal reasons in the GnRHa group),\nleaving 35 and 34 patients, respectively, for the final anal-\nysis (Fig. 1).\n2.2 Inclusion Criteria\nThe inclusion criteria were: (1) age between 23 and\n35 years; (2) diagnosed with OEMs only; other subtypes\nof endometriosis (e.g., deep infiltrating endometriosis or\nperitoneal endometriosis) were not included. (3) no previ-\nous surgical history related to endometriosis; OEMs were\ndiagnosed by experienced clinicians using transvaginal ul-\ntrasonography, according to the International Ovarian Tu-\nmor Analysis (IOTA) consensus criteria [ 7], characterized\nby cysts with regular margins and homogeneous low-level\n“ground-glass” echogenicity; (4) normal ovarian response\nmeeting the following criteria [ 8]: (a) a basal follicle-\nstimulating hormone (FSH) level below 10 IU/L; (b) bi-\nlateral antral follicle count (AFC) between 7 and 14; (c)\nanti-Müllerian hormone (AMH) between 1.0 ng/mL and 4.0\nng/mL; (d) no history of ovarian-stimulation-cycle cancel-\nlation prior to oocyte retrieval due to poor or excessive ovar-\nian response.\n2.3 Exclusion Criteria\nThe exclusion criteria were: (1) either partner pre-\nsenting with chromosomal abnormalities; (2) uterine ab-\nnormalities (e.g., congenital malformations, adenomyosis,\nor leiomyoma), endometrial lesions (e.g., endometritis,\npolyps, or intrauterine adhesions), or hydrosalpinx that may\naffect embryo implantation; (3) endocrine, immunologic, or\nmetabolic disorders such as thyroid disease, diabetes melli-\ntus, hyperprolactinemia, or polycystic ovary syndrome; (4)\nmale factor infertility, particularly severe male factor de-\nfined as total motile sperm count <5 × 10 6 in the male part-\nner [ 9], thereby minimizing the potential confounding ef-\nfect of male-related factors on IVF outcomes; (5) severe\nsystemic diseases, including major organ dysfunction, ma-\nlignancy, or a history of thromboembolic events; (6) poor\novarian responders and high ovarian responders, were ex-\ncluded to ensure a homogeneous population of normal ovar-\nian responders.\nThis retrospective study was approved by the Ethics\nCommittee of our hospital. The requirement for written\ninformed consent was waived due to the retrospective na-\nture of the study. Ethical approval was obtained after com-\npletion of patient follow-up, and all data were anonymized\nprior to analysis.\n2.4 Controlled Ovarian Stimulation Protocols\nPatients were not randomly assigned in this retrospec-\ntive study; instead, the allocation to each treatment group\nwas based on clinical decision-making, considering physi-\ncian preference and patient-specific conditions at the time\nof treatment. Two different controlled ovarian stimulation\nprotocols were implemented as described below:\nGnRHa group (n = 35): On menstrual cycle days 1–3,\npatients received an injection of triptorelin acetate 3.75 mg,\ns.c. (Decapeptyl, Ferring Pharmaceuticals SA, Saint-Prex,\nSwitzerland). The injection was repeated after 30 days for\na total of two doses.\n2\n\n\nFig. 1. Flow diagram of the study . GnRHa, gonadotropin-releasing hormone agonist; LE, letrozole.\nGnRHa + LE group (n = 36): On menstrual cycle\ndays 1–3, patients underwent the same GnRHa pretreatment\nas described above and received 2.5 mg LE (Jiangsu Hen-\ngrui Pharmaceuticals Co., Ltd., 231205KL, Lianyungang,\nJiangsu, China) orally once daily for five consecutive days.\nThirty days after the last GnRHa injection, vaginal ul-\ntrasonography was performed to assess antral follicle num-\nber and size. Serum concentrations of fFSH, luteinizing\nhormone (LH), and estradiol (E 2) were assessed. Pituitary\ndownregulation [ 10] was defined as the presence of folli-\ncles with a diameter ≤10 mm, accompanied by serum FSH\nand LH levels below 5 mIU/mL and an E2 level <50 pg/mL.\nControlled ovarian stimulation was then initiated with\nrecombinant FSH (r-FSH, Gonal-F, Merck Serono GmbH,\nBA089041/BA096091, Darmstadt, Germany) at 150–225\nIU combined with recombinant LH (r-LH, Luveris, Merck\nSerono GmbH, AU035478/AU043747, Darmstadt, Ger-\nmany) at 75 IU daily. Dosages were adjusted accord-\ning to individual ovarian response. When at least one\nfollicle reached ≥18 mm or two follicles reached ≥17\nmm, ovulation was triggered using recombinant human\nchorionic gonadotropin (r-hCG, Ovitrelle, Merck Serono,\nBA091066/BA096099, Modugno, Bari, Italy) 0.25 mg, s.c.\nOocyte collection was carried out 36–37 hours after trigger\nadministration, guided by transvaginal ultrasonography.\n2.5 Fertilization, Embryo Transfer , and Luteal Support\nSemen samples were produced from the male part-\nners by masturbation on the day of oocyte retrieval and col-\nlected. All cycles in this study were performed using con-\nventional IVF, as patients with severe male-factor infertil-\nity were excluded. Fertilization was assessed by the pres-\nence of two pronuclei (2PN) at 16–18 h after insemination.\nEmbryo morphology was assessed according to the Istanbul\nconsensus [11].\nPatients in the downregulation group received proges-\nterone (Zhejiang Xianju Pharmaceutical Co., Ltd., FB2439,\nXianju County, Taizhou, Zhejiang, China), 60 mg/day i.m.,\nand oral estradiol-dydrogesterone tablets (Femoston, Ab-\nbott Biologicals B.V ., 370364/374233, Olst, Netherlands;\ncontaining 2 mg estradiol and 10 mg dydrogesterone, twice\ndaily) for luteal-phase support.\nOn day 3 post-fertilization, embryo transfer (ET) was\nperformed under ultrasound guidance, with the number of\nembryos (one or two) determined according to endometrial\nthickness, serum hormone profiles, and embryo quality.\nRemaining viable embryos were cryopreserved for frozen-\nthawed embryo transfer (FET) if fresh transfer was not car-\nried out.\n2.6 Pregnancy Assessment and Follow-Up\nSerum β-human chorionic gonadotropin (β-hCG) con-\ncentrations were assessed 14 days following ET. Levels ≤5\nmIU/mL indicated implantation failure. Clinical pregnancy\nwas diagnosed when transvaginal ultrasonography at 28–35\ndays after ET demonstrated both a gestational sac and fetal\ncardiac activity.\n2.7 Outcome Measures\nBaseline characteristics were: age; duration of infer-\ntility; body mass index (BMI); AFC; AMH; basal hormone\nlevels (FSH, E 2); and mean maximum diameter of OEMs.\nStimulation and laboratory parameters were: dura-\ntion and total dose of gonadotropin; number of retrieved\noocytes; number of metaphase II (MII) oocytes; fertiliza-\ntion rate; cleavage rate; day-3 high-quality embryo rate;\nserum E 2 and progesterone levels on trigger day; endome-\ntrial thickness; number of embryos transferred; and fresh\nembryo-transfer-cancellation rate.\n3\n\nPregnancy outcomes were: mean maximum diameter\nof OEMs on trigger day; implantation rate; clinical preg-\nnancy rate; and early miscarriage rate.\n2.8 Definitions of Indicators\nThe indicators were defined according to previously\npublished studies [11,12,13].\n● The total number of oocytes retrieved referred to all\noocytes collected during the oocyte retrieval procedure.\n● MII oocytes were defined as mature oocytes char-\nacterized by the extrusion of the first polar body.\n● The fertilization rate was calculated as the pro-\nportion of oocytes successfully fertilized among all MII\noocytes.\n● The cleavage rate represented the percentage of em-\nbryos that underwent cleavage relative to the number of nor-\nmally fertilized oocytes.\n● The proportion of high-quality embryos on day 3\nwas defined as the number of good-quality embryos divided\nby the total number of cleaved embryos derived from nor-\nmally fertilized (2PN) zygotes.\n● The cancellation rate of fresh embryo transfer cy-\ncles was calculated based on the proportion of cycles in\nwhich embryo transfer was not performed among all oocyte\nretrieval cycles.\n● The implantation rate was defined as the ratio of\nsuccessfully implanted embryos to the total number of em-\nbryos transferred.\n● The clinical pregnancy rate was calculated as the\nproportion of cycles resulting in clinical pregnancy among\nall embryo transfer cycles.\n● Early miscarriage rate = (number of early miscar-\nriages ÷ number of clinical pregnancies) × 100%.\n2.9 Statistical Analysis\nAll statistical analyses were carried out with SPSS\n19.0 (IBM Corp., Armonk, NY , USA). Continuous vari-\nables were summarized as mean ± SD and analyzed using\nthe independent samples t-test for between-group compar-\nisons. Before applying the t-test, the normality of continu-\nous variables was assessed using the Shapiro–Wilk test, and\nhomogeneity of variances was evaluated using Levene’s\ntest. If the assumptions for the t-test were not met, non-\nparametric tests (Mann–Whitney U, Chi-square, Fisher’s\nexact) were used, as appropriate. With the actual analyzed\nsample sizes of 35 and 34, the post hoc statistical power\nto detect differences in embryos transferred and endome-\ntrial thickness was approximately 12.8% and 5.7%, respec-\ntively, using a two-tailed, two-sample t-test with unequal\nvariances at a significance level of 0.05. A p-value ≤ 0.05\nwas considered statistically significant.\n3. Results\n3.1 Baseline Characteristics of the Study Population\nBaseline demographic and clinical parameters were\ncomparable between the two groups. No significant dif-\nferences were observed in age, duration of infertility, BMI,\nAFC, AMH, basal FSH, basal E 2 levels, or the mean maxi-\nmal diameter of OEMs (all p > 0.05) (Table 1).\n3.2 Ovarian Stimulation Outcomes and Embryological\nCharacteristics\nCompared with the GnRHa protocol alone, patients\nreceiving the combined GnRHa + LE regimen required a\nlower total dose of gonadotropin and exhibited reduced\nserum E 2 concentrations on the day of trigger (both p\n< 0.05). In contrast, the GnRHa + LE group yielded a\ngreater number of retrieved and MII oocytes, along with\nimproved fertilization outcomes and a higher proportion of\nhigh-quality embryos on day 3 ( p < 0.05 for all compar-\nisons). However, no significant differences were identi-\nfied between the two groups in the duration of stimulation,\ncleavage rate, or progesterone level on the trigger day ( p >\n0.05) (Table 2).\n3.3 Comparison of Treatment Outcomes and Pregnancy\nResults\nFresh embryo transfer was carried out in 35 cycles in\nthe GnRHa + LE group and in 34 cycles in the GnRHa\ngroup. Baseline transfer characteristics, including the num-\nber of embryos transferred, endometrial thickness on the\ntransfer day, and the rate of ET cancellation, were compa-\nrable between the two groups (all p > 0.05). Compared with\nthe GnRHa group, the GnRHa + LE group demonstrated a\nsignificantly higher clinical pregnancy rate, along with an\nincreased implantation rate (all p < 0.05) and a compara-\nble incidence of early miscarriage ( p = 0.82). In addition,\nthe mean maximum diameter of OEMs was significantly\nsmaller in the GnRHa + LE group than in the GnRHa group\nafter pretreatment (p < 0.05) (Table 3).\n4. Discussion\nEndometriosis is an estrogen-dependent disease in\nwhich increased estrogen sensitivity and progesterone re-\nsistance play critical roles in onset and progression. The\ndisease has an insidious onset and begins to impair fertility\neven at its early stage, with an average diagnostic delay of\napproximately 10 years [ 14]. A study has shown that 22–\n63% of women with unexplained infertility who undergo\nlaparoscopy are found to have endometriosis [ 15]. As the\ndisease progresses, ectopic endometrial tissue may invade\nthe pelvic cavity, ovaries, or peritoneum, leading to infer-\ntility through multiple mechanisms, including altered coital\nfrequency, ovulatory dysfunction, impaired tubal function,\nreduced embryo quality, and decreased endometrial recep-\ntivity [16]. In addition, endometriosis-associated peritoneal\nfluid may negatively affect sperm function [ 17]. An ex-\nperimental study showed that peritoneal fluid from women\nwith moderate to severe endometriosis can impair sperm\nmotility, potentially due to elevated levels of reactive oxy-\ngen species and inflammatory cytokines (e.g., tumor necro-\nsis factor-alpha [TNF-α], interleukin-6 [IL-6], interleukin-\n4\n\n\nTable 1. Baseline characteristics of the study groups .\nV ariable GnRHa + LE group GnRHa group p V alue\nCycles (n) 36 35\nAge (years) 30.42 ± 3.55 (23–34) 29.03 ± 2.95 (25–35) 0.08\nType of Infertility, n (%) 0.73\nPrimary 22 (61.11%) 20 (57.14%)\nSecondary 14 (38.89%) 15 (42.86%)\nDuration of Infertility (years) 3.38 ± 1.00 3.11 ± 1.13 0.31\nBMI (kg/m2) 22.54 ± 1.99 21.90 ± 1.79 0.16\nAFC (n) 10.36 ± 2.67 10.71 ± 2.52 0.57\nAMH (ng/mL) 2.69 ± 0.70 2.63 ± 0.62 0.70\nBasal FSH (mIU/mL) 7.74 ± 1.36 7.34 ± 1.78 0.29\nBasal E2 (pg/mL) 41.00 (32.00, 65.00) 40.00 (33.00, 60.95) 0.74\nMax diameter (mm) 33.67 ± 5.86 32.13 ± 5.07 0.24\nNote: BMI, body mass index; AMH, anti-Müllerian hormone; AFC, antral follicle count; Basal FSH, basal\nfollicle-stimulating hormone; Basal E2, basal estradiol; Max diameter, mean maximum diameter of ovarian\nendometriomas. Data are presented as mean ± SD, median (IQR), or n (%), as appropriate.\nTable 2. Ovarian stimulation outcomes and embryological variables in the two groups [(mean ± SD), %] .\nV ariable GnRHa + LE group GnRHa group p V alue\nCycles (n) 36 35\nStimulation Days 9.97 ± 1.70 9.83 ± 1.62 0.72\nTotal Gonadotropin Dose (IU) 2182 ± 406.6 2705 ± 416.6 <0.01\nOocytes Retrieved 9.11 ± 2.52 6.97 ± 1.86 <0.01\nMII Oocytes 6.75 ± 2.37 4.80 ± 1.55 <0.01\nFertilization Rate (%) 87.24 (212/243) 77.38 (130/168) 0.01\nCleavage Rate (%) 90.09 (191/212) 87.69 (114/130) 0.12\nDay 3 high-quality embryo rate (%) 60.73 (116/191) 49.12 (56/114) <0.05\nE2 (pg/mL) 1981 ± 556.10 2924 ± 730.50 <0.01\nP (ng/mL) 0.83 ± 0.34 0.91 ± 0.18 0.20\nNote: MII, metaphase II; E 2, estradiol; P , progesterone.\nTable 3. Treatment and pregnancy outcomes in the two groups [(mean ± SD), %] .\nV ariable GnRHa +LE group GnRHa group p V alue\nTotal cycles (n) 36 35\nFresh embryo transfer cycles (n) 35 34\nMax diameter (mm) 27.14 ± 5.65 29.72 ± 4.68 0.04\nEmbryos Transferred 1.51 ± 0.51 1.41 ± 0.50 0.40\nEndometrial Thickness (mm) 10.86 ± 4.33 10.66 ± 2.01 0.81\nFresh embryo transfer cancellation rate (%) 2.78 (1/36) 2.86 (1/35) 1.00\nImplantation Rate (%) 41.51 (22/53) 22.92 (11/48) 0.04\nClinical Pregnancy Rate (%) 57.14 (20/35) 32.35 (11/34) 0.04\nEarly Miscarriage Rate (%) 15.00 (3/20) 18.18 (2/11) 1.00\nNote: Embryos transferred and endometrial thickness were analyzed among fresh embryo\ntransfer cycles (n = 35 in the GnRHa + LE group and n = 34 in the GnRHa group). The fresh\nembryo transfer cancellation rate was calculated based on all initiated cycles (n = 36 and n\n= 35, respectively).\n8 [IL-8]), which may interfere with sperm capacitation and\nacrosome reaction [ 18]. However, the application of as-\nsisted reproductive technology enables the majority of pa-\ntients to attain favorable reproductive outcomes.\nOEMs represent an advanced stage of the disease. The\ncysts can impair ovarian function through mechanical com-\npression and the secretion of inflammatory cytokines, reac-\ntive oxygen species, and free iron, thereby reducing ovarian\nresponsiveness, impairing oocyte development, and com-\npromising embryo quality, which ultimately affects IVF-\nET outcomes [ 2]. An in vitro study has demonstrated that\nexposure of parthenogenetically activated oocytes to follic-\n5\n\nular fluid from patients with OEMs significantly increases\noocyte fragmentation and cell death, thereby impairing em-\nbryonic development [19].\nGnRHa is among the most widely used classes of med-\nications for the treatment of endometriosis. A GnRHa binds\nto gonadotropin-releasing hormone receptors on the ante-\nrior pituitary with high affinity, initially producing a “flare-\nup effect” that transiently elevates FSH and LH levels and\npromotes follicular development. With prolonged adminis-\ntration, however, receptor desensitization and downregula-\ntion occur, leading to suppression of gonadotropin secretion\nand reduced estrogen levels. As a result, ectopic endome-\ntrial tissue undergoes atrophy due to estrogen deprivation,\nthereby relieving symptoms and improving fertility in pa-\ntients with endometriosis [ 20].\nMost studies have demonstrated that pretreatment\nwith GnRHa for 3–6 months before Assisted Reproductive\nTechnology (ART) improves clinical outcomes in patients\nwith advanced endometriosis (stage III–IV), although its\nbenefit in mild disease remains controversial [ 21,22]. The\nmechanisms by which GnRHa enhances IVF outcomes are\nmultifactorial. GnRHa reduces the expression of vascu-\nlar endothelial growth factor, tissue factor, and protease-\nactivated receptor 2 in ectopic endometrium, thereby in-\nhibiting angiogenesis and reducing cell adhesion and inva-\nsion [23]. In addition, GnRHa decreases the production of\ncytotoxic factors in follicular fluid, reduces oxidative stress,\nand improves oocyte quality. After three months of GnRHa\ntreatment, the concentrations of TNF-α and 8-hydroxy-2′-\ndeoxyguanosine in follicular fluid are significantly reduced,\nwhereas melatonin levels and fertilization rates are higher\n[24].\nGnRHa also improves endometrial receptivity by pro-\nmoting the development of pinopodes. Li et al. [ 25]\nreported that GnRHa pretreatment downregulated miR-\n124-3p expression and upregulated IL-6, IL-11, Leukemia\nInhibitory Factor (LIF), and integrin αvβ3 in the en-\ndometrium, which favored early embryo implantation. Fur-\nthermore, GnRHa enhanced subendometrial blood perfu-\nsion and improved the pelvic inflammatory environment\n[26]. However, whether GnRHa reduces the size of en-\ndometriotic lesions remains unclear. GnRHa primarily sup-\npresses ovarian estrogen production but does not affect es-\ntrogen derived from ectopic endometrial tissue, adrenal cor-\ntex, or peripheral aromatization, which may explain why\nsome cases are resistant to ovarian suppression [ 5].\nAs a third-generation aromatase inhibitor, LE sup-\npresses estrogen production at both central and peripheral\nlevels, thereby establishing a hormonal milieu that more\nclosely resembles physiological conditions. A study has\nshown that LE effectively reduces serum E 2 levels on the\nday of trigger and lowers E 2 production per mature folli-\ncle without compromising ovulation-induction outcomes,\nthereby reducing estrogen exposure and potentially limiting\ndisease progression. It is widely considered a relatively safe\noption for ovulation induction when fertility preservation is\nrequired in individuals with hormone-sensitive gynecologic\nmalignancies [27].\nLE has also been shown to improve ovarian re-\nsponse and endometrial receptivity. Among women with\npoor ovarian response, co-administration of LE with go-\nnadotropins was associated with increased yields of re-\ntrieved oocytes, MII oocytes, and high-quality embryos\ncompared with gonadotropin stimulation alone [28]. In hor-\nmone replacement embryo-transfer cycles, the addition of\nLE was linked to increased pregnancy rates, likely due to\nenhanced endometrial receptivity through molecular mech-\nanisms [ 29]. An animal study has demonstrated that LE\nincreased the expression of αvβ3 integrin and Homeobox\nA10 (HOXA10), two markers of endometrial receptivity,\nin rat endometrium [ 30].\nCombined treatment with GnRHa and LE provided\nmaximal suppression of estrogen production and reduced\ninflammatory mediators in endometrial tissue. This com-\nbined approach has been shown to enhance both the like-\nlihood of achieving a clinical pregnancy and the chance of\nlive birth among women experiencing repeated implanta-\ntion failure or unexplained endometriosis [ 31]. Cozzolino\net al. [ 32] reported that GnRHa monotherapy may be in-\nsufficient to suppress estrogen secretion in severe adeno-\nmyosis, whereas combination therapy with LE was both\nsafe and effective. Similarly, previous studies [ 33,34] sug-\ngest that combining an aromatase inhibitor with GnRHa\nmay improve reproductive outcomes in women with en-\ndometriosis. Moreover, since endometriotic epithelial cells\nharbor oncogenic mutations and endometriosis is linked to\na higher risk of ovarian cancer in ART patients [ 35], the\ncombination of GnRHa and LE may also reduce estrogen\nexposure and help prevent malignant transformation.\nIn the present study, GnRHa combined with LE sig-\nnificantly reduced E 2 level on the day of trigger and led to\na greater reduction in the mean diameter of OEMs than did\nGnRHa alone. Notably, patients in the combination group\nachieved superior reproductive outcomes, including greater\noocyte yield, increased numbers of MII oocytes, improved\nfertilization rates, a higher proportion of good-quality em-\nbryos on day 3, as well as enhanced clinical pregnancy rates.\nWe selected individuals diagnosed with OEM who ex-\nhibited a normal ovarian response to minimize the influ-\nence of hyper- or hypo-response on the study outcomes.\nThe half-life of LE is 30–60 h, and its optimal dose in\nART remains uncertain [36]. Given that higher doses of LE\nmay promote multifollicular development and potentially\nincrease the risk of ovarian hyperstimulation and multiple\npregnancy, we adopted a commonly used low-dose regimen\nof 2.5 mg/day for five days [ 37]. Although some patients\nin the combination group experienced mild hypoestrogenic\nsymptoms, no severe adverse reactions were observed.\nLimitations\nThis study had several limitations that should be ac-\nknowledged. First, preimplantation genetic testing was not\n6\n\n\nperformed, which may have limited a comprehensive eval-\nuation of embryo quality. Second, the relatively small sam-\nple size may have limited the statistical power to detect dif-\nferences in certain outcomes. As indicated by the post hoc\npower analysis, the power for several nonsignificant vari-\nables, including the number of embryos transferred and en-\ndometrial thickness, was less than 20%, indicating a high\nrisk of type II error. Therefore, due to sample size limi-\ntations, it is not possible to conclude that there is no dif-\nference between the two groups for these outcomes. The\nabsence of statistically significant differences should be in-\nterpreted with caution, as true differences may have been\nmissed. Third, the optimal dose and duration of LE in this\npopulation remain unclear and require further investigation.\nFourth, only patients with OEM were included, which may\nhave restricted the generalizability of the findings. Consid-\nering the heterogeneous nature of endometriosis, our results\nmay not be directly applicable to other subtypes, such as\ndeep infiltrating or peritoneal endometriosis. Finally, given\nthe retrospective design and the lack of randomization, po-\ntential selection bias cannot be entirely excluded.\n5. Conclusions\nFor patients with OEMs and normal ovarian response,\npretreatment with a combination of GnRHa and LE ap-\npeared to be more beneficial for reducing cyst size and\nimproving IVF-ET pregnancy outcomes than did pretreat-\nment with GnRHa alone. Large-scale randomized con-\ntrolled studies are needed in order to validate these findings.\nAvailability of Data and Materials\nThe datasets generated and analyzed during the cur-\nrent study are available from the corresponding author upon\nreasonable request.\nAuthor Contributions\nYC and YY were involved in data interpretation. JG\ncontributed substantially to the acquisition, curation, verifi-\ncation, and interpretation of the clinical data. QS conceived\nthe study and performed the data analysis. All authors par-\nticipated in manuscript revision, approved the final version,\nand agree to be accountable for all aspects of the work.\nEthics Approval and Consent to Participate\nThis study adhered to the principles of the Declara-\ntion of Helsinki and received approval from the Reproduc-\ntive Medicine Ethics Committee of Xuzhou Central Hospi-\ntal (Approval No. XZXY -LS-20250624-002). The require-\nment for written informed consent was waived by the Ethics\nCommittee due to the retrospective nature of the study.\nAcknowledgment\nWe sincerely thank all individuals who contributed to\nthe preparation of this manuscript. We are also grateful to\nthe peer reviewers for their valuable comments and con-\nstructive suggestions.\nFunding\nThis research received no external funding.\nConflicts of Interest\nThe authors declare no conflicts of interest.\nSupplementary Material\nSupplementary material associated with this article\ncan be found, in the online version, at https://doi.org/10.\n31083/CEOG50028.\nReferences\n[1] Horne AW, Missmer SA. Pathophysiology, diagnosis, and man-\nagement of endometriosis. BMJ. 2022; 379: e070750. https:\n//doi.org/10.1136/bmj-2022-070750\n[2] Hodgson RM, Lee HL, Wang R, Mol BW, Johnson N. Interven-\ntions for endometriosis-related infertility: a systematic review\nand network meta-analysis. Fertility and Sterility. 2020; 113:\n374–382.e2. https://doi.org/10.1016/j.fertnstert.2019.09.031\n[3] Sallam HN, Garcia-V elasco JA, Dias S, Arici A. Long-term pi-\ntuitary down-regulation before in vitro fertilization (IVF) for\nwomen with endometriosis. The Cochrane Database of System-\natic Reviews. 2006; 2006: CD004635. https://doi.org/10.1002/\n14651858.CD004635.pub2\n[4] Hao H, Li M, Zhang C, Zhang S. The effect of gonadotropin-\nreleasing hormone agonist downregulation in conjunction\nwith hormone replacement therapy on endometrial prepara-\ntion in patients for frozen-thawed embryo transfer. Frontiers\nin Medicine. 2024; 11: 1412126. https://doi.org/10.3389/fmed\n.2024.1412126\n[5] Clemenza S, V annuccini S, Ruotolo A, Capezzuoli T, Pe-\ntraglia F. Advances in targeting estrogen synthesis and recep-\ntors in patients with endometriosis. Expert Opinion on Investi-\ngational Drugs. 2022; 31: 1227–1238. https://doi.org/10.1080/\n13543784.2022.2152325\n[6] Agarwal SK, Foster WG. Reduction in Endometrioma Size with\nThree Months of Aromatase Inhibition and Progestin Add-Back.\nBioMed Research International. 2015; 2015: 878517. https://do\ni.org/10.1155/2015/878517\n[7] Timmerman D, V alentin L, Bourne TH, Collins WP , V errelst\nH, V ergote I, et al. Terms, definitions and measurements to de-\nscribe the sonographic features of adnexal tumors: a consensus\nopinion from the International Ovarian Tumor Analysis (IOTA)\nGroup. Ultrasound in Obstetrics & Gynecology: the Official\nJournal of the International Society of Ultrasound in Obstetrics\nand Gynecology. 2000; 16: 500–505. https://doi.org/10.1046/j.\n1469-0705.2000.00287.x\n[8] La Marca A, Sunkara SK. Individualization of controlled ovar-\nian stimulation in IVF using ovarian reserve markers: from the-\nory to practice. Human Reproduction Update. 2014; 20: 124–\n140. https://doi.org/10.1093/humupd/dmt037\n[9] Chen ZJ, Liu JY , Huang HF, Qiao J, Zhou CQ, Huang GN,\net al. Guidelines for the diagnosis and treatment of infertility.\nChinese Journal of Obstetrics and Gynecology. 2019; 54: 505–\n511. https://doi.org/10.3760/cma.j.issn.0529-567x.2019.08.001\n(In Chinese)\n[10] Lang JH, Leng JH, Y ang Q, Li R, Hua KQ, Zhang GN, et al. Chi-\nnese Expert Consensus on GnRH-a in Obstetrics and Gynecol-\nogy. Zhonghua Fu Chan Ke Za Zhi. 2025; 60: 913–925. https://\ndoi.org/10.3760/cma.j.cn112141-20250529-00244 (In Chinese)\n[11] Alpha Scientists in Reproductive Medicine and ESHRE Special\nInterest Group of Embryology. The Istanbul consensus work-\nshop on embryo assessment: proceedings of an expert meeting.\n7\n\nHuman Reproduction. 2011; 26: 1270–1283. https://doi.org/10.\n1093/humrep/der037\n[12] Sun Q, Cao Y , Gu J, Xu Y . The application of progesterone-\nprimed ovarian stimulation protocol in patients with ovar-\nian endometriosis combined with diminished ovarian reserve.\nBMC Women’s Health. 2025; 25: 70. https://doi.org/10.1186/\ns12905-025-03601-w\n[13] Zegers-Hochschild F, Adamson GD, de Mouzon J, Ishihara\nO, Mansour R, Nygren K, et al. The International Committee\nfor Monitoring Assisted Reproductive Technology (ICMART)\nand the World Health Organization (WHO) Revised Glossary\non ART Terminology, 2009. Human Reproduction. 2009; 24:\n2683–2687. https://doi.org/10.1093/humrep/dep343\n[14] Penzer AJ, Schweikart SJ. Using Policy and Law to Help Reduce\nEndometriosis Diagnostic Delay. AMA Journal of Ethics. 2025;\n27: E104–109. https://doi.org/10.1001/amajethics.2025.104\n[15] Hashemi M, Mohseni H, Ghahiri A, Rouholamin S. Laparo-\nscopic and Hysteroscopic Findings in A Selected Group of\nWomen with Unexplained Infertility: A Cross-Sectional Study.\nInternational Journal of Fertility & Sterility. 2024; 18: 339–343.\nhttps://doi.org/10.22074/ijfs.2023.2005476.1484\n[16] Latif S, Khanjani S, Saridogan E. Endometriosis and In Vitro\nFertilization. Medicina. 2024; 60: 1358. https://doi.org/10.3390/\nmedicina60081358\n[17] Oral E, Arici A, Olive DL, Huszar G. Peritoneal fluid from\nwomen with moderate or severe endometriosis inhibits sperm\nmotility: the role of seminal fluid components. Fertility\nand Sterility. 1996; 66: 787–792. https://doi.org/10.1016/\ns0015-0282(16)58637-3\n[18] Liu Y , Luo L, Zhao H. Changes of tumor necrosis factor al-\npha and interleukin-6 levels in peritoneal fluid of patients with\nendometriosis and their effects on human sperm motility and\nmouse embryo development. Zhonghua Fu Chan Ke Za Zhi.\n2000; 35: 332–334. (In Chinese)\n[19] Paffoni A, Bolis V , Ferrari S, Benaglia L, V ercellini P ,\nSomigliana E. The Gametotoxic Effects of the Endometrioma\nContent: Insights From a Parthenogenetic Human Model. Re-\nproductive Sciences. 2019; 26: 573–579. https://doi.org/10.\n1177/1933719118777637\n[20] V eth VB, van de Kar MM, Duffy JM, van Wely M, Mija-\ntovic V , Maas JW. Gonadotropin-releasing hormone analogues\nfor endometriosis. The Cochrane Database of Systematic Re-\nviews. 2023; 6: CD014788. https://doi.org/10.1002/14651858.\nCD014788.pub2\n[21] Becker CM, Bokor A, Heikinheimo O, Horne A, Jansen F, Kiesel\nL, et al. ESHRE guideline: endometriosis. Human Reproduction\nOpen. 2022; 2022: hoac009. https://doi.org/10.1093/hropen/hoa\nc009\n[22] Sõritsa D, Saare M, Laisk-Podar T, Peters M, Sõritsa A, Matt\nK, et al. Pregnancy rate in endometriosis patients according to\nthe severity of the disease after using a combined approach of\nlaparoscopy, GnRH agonist treatment and in vitro fertilization.\nGynecologic and Obstetric Investigation. 2015; 79: 34–39. http\ns://doi.org/10.1159/000365329\n[23] Filindris T, Papakonstantinou E, Keramida M, Panteris E,\nKalogeropoulos S, Georgopoulos N, et al. The effect of GnRH-\na on the angiogenesis of endometriosis. Hormones. 2024; 23:\n509–515. https://doi.org/10.1007/s42000-024-00559-6\n[24] Tamura H, Takasaki A, Nakamura Y , Numa F, Sugino N. A pilot\nstudy to search possible mechanisms of ultralong gonadotropin-\nreleasing hormone agonist therapy in IVF-ET patients with en-\ndometriosis. Journal of Ovarian Research. 2014; 7: 100. https:\n//doi.org/10.1186/s13048-014-0100-8\n[25] Li L, Liu L, Kou Z, Huo M, An J, Zhang X. GnRH agonist\ntreatment regulates IL-6 and IL-11 expression in endometrial\nstromal cells for patients with HRT regiment in frozen em-\nbryo transfer cycles. Reproductive Biology. 2022; 22: 100608.\nhttps://doi.org/10.1016/j.repbio.2022.100608\n[26] Panagodimou EK, Kalogeropoulos S, Adonakis G, Kaponis A.\nDoes Gonadotropin-Releasing Hormone Agonist Administra-\ntion Before Assisted Reproduction Techniques Improve Preg-\nnancy Rates in Women With Endometriosis? Obstetrical &\nGynecological Survey. 2024; 79: 421–428. https://doi.org/10.\n1097/OGX.0000000000001283\n[27] Suzuki R, Horage-Okutsu Y , Kawahara T, Nakamura K, Shi-\nraishi E, Iwahata H, et al. The effect of aromatase inhibitor\non controlled ovarian stimulation for oocyte cryopreservation\nin adolescent and young cancer patients. The Journal of Ob-\nstetrics and Gynaecology Research. 2023; 49: 973–979. https:\n//doi.org/10.1111/jog.15535\n[28] Shapira M, Orvieto R, Lebovitz O, Nahum R, Aizer A,\nSegev-Zahav A, et al. Does daily co administration of go-\nnadotropins and letrozole during the ovarian stimulation im-\nprove IVF outcome for poor and sub optimal responders? Jour-\nnal of Ovarian Research. 2020; 13: 66. https://doi.org/10.1186/\ns13048-020-00666-z\n[29] Elgindy EA, Abdelghany AA, Sibai AbdAlsalam H, Mostafa\nMI. The novel incorporation of aromatase inhibitor in hormonal\nreplacement therapy cycles: a randomized controlled trial. Re-\nproductive Biomedicine Online. 2022; 44: 641–649. https://doi.\norg/10.1016/j.rbmo.2021.10.025\n[30] Zhang J, Wang L, Li C, Zhang H, Li R, Li M. Letrozole pro-\nmotes the expression of integrin αvβ3 and HOXA10 in en-\ndometrium of endometriosis. Systems Biology in Reproduc-\ntive Medicine. 2022; 68: 121–128. https://doi.org/10.1080/\n19396368.2021.2013577\n[31] Steiner N, Shrem G, Tannus S, Dahan SY , Balayla J,\nV olodarsky-Perel A, et al. Effect of GnRH agonist and letrozole\ntreatment in women with recurrent implantation failure. Fertil-\nity and Sterility. 2019; 112: 98–104. https://doi.org/10.1016/j.fe\nrtnstert.2019.03.021\n[32] Cozzolino M, Pellicer N, Galliano D, Pellicer A. Pituitary\nsuppression with GnRH agonists before ART may be insuffi-\ncient to treat women with severe adenomyosis. Reproductive\nBiomedicine Online. 2023; 46: 150–155. https://doi.org/10.\n1016/j.rbmo.2022.09.023\n[33] Piedimonte S, V olodarsky-Perel A, Tannus S, Tan SL, Dahan\nMH. Pretreatment with a gonadotropin-releasing hormone ag-\nonist and an aromatase inhibitor may improve outcomes in in\nvitro fertilization cycles of women with stage I-II endometrio-\nsis. F&S Science. 2020; 1: 98–103. https://doi.org/10.1016/j.xf\nss.2020.06.005\n[34] Cantor A, Tannus S, Son WY , Tan SL, Dahan MH. A com-\nparison of two months pretreatment with GnRH agonists with\nor without an aromatase inhibitor in women with ultrasound-\ndiagnosed ovarian endometriomas undergoing IVF. Reproduc-\ntive Biomedicine Online. 2019; 38: 520–527. https://doi.org/10.\n1016/j.rbmo.2018.12.028\n[35] Y oshihara K. Pathogenesis of endometrium-related diseases\nbased on genomic alterations in normal uterine endometrium.\nThe Journal of Obstetrics and Gynaecology Research. 2023; 49:\n2023–2030. https://doi.org/10.1111/jog.15680\n[36] Pritts EA. Letrozole for ovulation induction and controlled ovar-\nian hyperstimulation. Current Opinion in Obstetrics & Gynecol-\nogy. 2010; 22: 289–294. https://doi.org/10.1097/GCO.0b013e\n32833beebf\n[37] Tatsumi T, Jwa SC, Kuwahara A, Irahara M, Kubota T, Saito\nH. No increased risk of major congenital anomalies or adverse\npregnancy or neonatal outcomes following letrozole use in as-\nsisted reproductive technology. Human Reproduction. 2017; 32:\n125–132. https://doi.org/10.1093/humrep/dew280\n8","source_license":"CC0","license_restricted":false}